← back to search

Hushan Yang

Thomas Jefferson University · US
Area of research
Cancer Research · Otorhinolaryngology
Research interest
Research focused on Mitochondrial DNA and Biosimilar, with related work in Hepatocellular carcinoma, Anemia, Downregulation and upregulation. Notable publications include 'Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update', 'Hypoxia upregulates CD147 through a combined effect of HIF-1α and Sp1 to promote glycolysis and tumor progression in epithelial solid tumors', and 'Cell-free circulating mitochondrial DNA content and risk of hepatocellular carcinoma in patients with chronic HBV infection'.
h-index
citations
671
works
10
NIH funding
primary concept
email

Recent publications

1605MO Primary results from a randomized phase II trial of BNT111 in combination with cemiplimab with calibrator monotherapy arms in anti-PD-(L)1 relapsed/refractory melanoma
Annals of Oncology 2025cited by 5position: middledoi
Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update
Blood Advances 2019cited by 162position: middledoi
Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update
Journal of Clinical Oncology 2019cited by 140position: middledoi
Site-specific selection reveals selective constraints and functionality of tumor somatic mtDNA mutations
Journal of Experimental & Clinical Cancer Research 2017cited by 11position: middledoi
Cell-free circulating mitochondrial DNA content and risk of hepatocellular carcinoma in patients with chronic HBV infection
Scientific Reports 2016cited by 92position: lastdoi
Prospective changes in global DNA methylation and cancer incidence and mortality
British Journal of Cancer 2016cited by 50position: middledoi
Prospective evidence of a circulating microRNA signature as a non-invasive marker of hepatocellular carcinoma in HBV patients
Oncotarget 2016cited by 15position: lastdoi
CD147-CD98hc Complex Contributes to Poor Prognosis of Non-Small Cell Lung Cancer Patients Through Promoting Cell Proliferation Via the PI3K/Akt Signaling Pathway
Annals of Surgical Oncology 2014cited by 52position: middledoi
Racial disparity in breast cancer survival: the impact of pre-treatment hematologic variables
Cancer Causes & Control 2014cited by 17position: lastdoi
Hypoxia upregulates CD147 through a combined effect of HIF-1α and Sp1 to promote glycolysis and tumor progression in epithelial solid tumors
Carcinogenesis 2012cited by 127position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Jinliang Xing · Thomas Jefferson University6 papers (2012–2017)Bingshan Li · Vanderbilt University4 papers (2014–2017)Ronald E. Myers · Thomas Jefferson University3 papers (2014–2016)Deyang Li · Queen's University2 papers (2014–2017)Xu Guo · Nanjing University of Chinese Medicine2 papers (2014–2017)Zhong Ye · Boston Medical Center2 papers (2014–2016)Jesse Civan · Thomas Jefferson University2 papers (2014–2016)Kari Bohlke · Northwell Health2 papers (2019–2019)Shaogui Wan · Thomas Jefferson University2 papers (2016–2016)Tiffany Tanaka · Sanford Consortium for Regenerative Medicine2 papers (2019–2019)Hie‐Won Hann · Thomas Jefferson University2 papers (2016–2016)Zhi‐Nan Chen · The Ohio State University2 papers (2012–2014)Massimo Cristofanilli · NewYork–Presbyterian Brooklyn Methodist Hospital2 papers (2014–2016)Richard S. Hann · Thomas Jefferson University2 papers (2016–2016) · 2 papers (2019–2019)Giannis Mountzios · National and Kapodistrian University of Athens2 papers (2019–2019)Li Xu · Jiangxi University of Traditional Chinese Medicine2 papers (2012–2014)Gianluca Trifirò · University of Verona2 papers (2019–2019)Alejandro Lazo‐Langner · Western University2 papers (2019–2019)Yinzhi Lai · University of Georgia2 papers (2014–2016)